GenMark Diagnostics (GNMK) Reports In-Line Q1 EPS, Maintains FY Outlook

GenMark Diagnostics (NASDAQ: GNMK) reported Q1 EPS of ($0.24), in-line with the analyst estimate of ($0.24). Revenue for the quarter came in at $10.1 million versus the consensus estimate of $10.1 million.

For full year 2015, the Company continues to expect revenue in the range of $38 to $40 million and gross margin in the range of 53-55%.

For earnings history and earnings-related data on GenMark Diagnostics (GNMK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c